middle.news
Biotron Taps C14 Consulting to Accelerate Antiviral Commercialisation
9:11am on Friday 24th of January, 2025 AEDT
•
Biotechnology
Read Story
Biotron Taps C14 Consulting to Accelerate Antiviral Commercialisation
9:11am on Friday 24th of January, 2025 AEDT
Key Points
Appointment of C14 Consulting Group to enhance commercial partnerships
Focus on antiviral programs with lead asset BIT225
Ongoing preclinical research targeting Hepatitis B virus
Reported $507,000 in R&D and staff expenditures for the quarter
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE